Table 1.
Inclusion and exclusion criteria
| Inclusion criteria | - Aged between 18 and 65 years |
| - Men and women | |
| - 2Patients undergoing myeloablative allo-HSCT for a haematological malignancy | |
| - HLA-compatibility: geno-identical or pheno-identical 10/10 | |
| - Patients affiliated with a social-security organisation | |
| - Patients had signed the informed consent | |
| Exclusion criteria | - Status of tumour progression at the moment of the allo-HSCT |
| - HLA compatibility ≤ 9/10 | |
| - Artificial nutrition used at the moment of inclusion | |
| - Inability to understand the protocol (linguistic barrier, cognitive difficulties) | |
| - Contraindication or associated pathology that does not allow us to carry out EN or PN according to the protocol | |
| - Medical history of progressive psychiatric illness | |
| - Medical history of another progressive cancer or occurrence in the 5 previous years | |
| - Presence of a simultaneous serious and uncontrolled disease, such as severe cardiac, renal, hepatic or respiratory failure, or severe sepsis | |
| - Previous allo-HSCT | |
| - Antibiotic use for digestive decontamination | |
| - Participation in another clinical trial studying an allograft procedure, and applying modalities that are not available in routine practice (including innovative immunosuppression and graft or conditioning regimens not considered as myeloablative). |